Читать книгу Blood and Marrow Transplantation Long Term Management - Группа авторов - Страница 162

1 1. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945–956.

2 2. Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft‐versus‐host disease (GVHD): first‐line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010; 16:1611–1628.

3 3. Greinix HT, Loddenkemper C, Pavletic SZ, et al. Diagnosis and staging of chronic graft‐versus‐host disease in the clinical practice. Biol Blood Marrow Transplant. 2011; 17:167–175.

4 4. Zeiser R, Blazar BR. Pathophysiology of chronic graft‐versus‐host disease and therapeutic targets. N Engl J Med. 2017; 377:2565–2579.

5 5. Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft‐versus‐Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft‐versus‐Host Disease. Biol Blood Marrow Transplant. 2017; 23:211–234.

6 6. Blazar BR, Murphy WJ, Abedi M. Advances in graft‐versus‐host disease biology and therapy. Nat Rev Immunol. 2012; 12:443–458.

7 7. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Ann Rev Immunol. 2007; 25:139–170.

8 8. Gea‐Banacloche J, Komanduri KV, Carpenter P, et al. National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. Biol Blood Marrow Transplant. 2017; 23:870–881.

9 9. Vogelsang GB. How I treat chronic graft‐versus‐host disease. Blood. 2001; 97:1196–1201.

10 10. Lee SJ, Vogelsang G, Flowers MED. Chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2003; 9:215–233.

11 11. Fuji S, Kapp M, Einsele H. Challenges to preventing infectious complications, decreasing re‐hospitalizations, and reducing cost burden in long‐term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49:10–14.

12 12. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009; 15:1143–1238.

13 13. Deeg HJ, Socie G. Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood. 1998; 91:1833–1844.

14 14. Adès L, Guardiola P, Sociè G. Second malignancies after allogeneic hematopoietic stem cell transplantation: new insight and current problems. Blood Rev. 2002; 16:135–146.

15 15. Majhail NS. Long‐term complications after hematopoietic cell transplantation. Hematol Oncol Stem Cell Ther. 2017; 10:220–227.

16 16. Battiwalla M, Tichelli A, Majhail NS. Long‐term survivorship after hematopoietic cell transplantation: roadmap for research and care. Biol Blood Marrow Transplant. 2017; 23:184–192.

17 17. Socié G, Salooja N, Cohen A, et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101:3373–3385.

18 18. Inamoto Y, Valdés‐Sanz N, Ogawa Y, et al. Ocular graft‐versus‐host disease after hematopoietic cell transplantation: Expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. Bone Marrow Transplant. 2019; 54:662–673.

19 19. Deeg HJ, Flournoy N, Sullivan KM, et al. Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation. Int J Radiat Oncol Biol Phys. 1984; 10:957–964.

20 20. Tichelli A, Gratwohl A, Egger T, et al. Cataract formation after bone marrow transplantation. Ann Intern Med. 1993; 119:1175–1180.

21 21. Benyunes MC, Sullivan KM, Deeg HJ, et al. Cataracts after bone marrow transplantation: long‐term follow‐up of adults treated with fractionated total body irradiation. Int J Radiat Oncol Biol Phys. 1995; 32:661–670.

22 22. Belkacémi Y, Ozsahin M, Pène F, et al. Cataractogenesis after total body irradiation. Int J Radiat Oncol Biol Phys. 1996; 35:53–60.

23 23. Belkacemi Y, Labopin M, Vernant JP, et al. Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation. Int J Radiat Oncol Biol Phys. 1998; 41:659–668.

24 24. Socié G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total‐body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long‐term follow‐up of 4 randomized studies. Blood. 2001; 98:3569–3574.

25 25. Gratwohl AA, Gratwhol AA, Moutsopoulos HM, et al. Sjögren‐type syndrome after allogeneic bone‐marrow transplantation. Ann Int Med. 1977; 87:703–706.

26 26. Mercier A, Devergie A, Arrago JP, et al. Systemic evaluation of Sjögren‐like syndrome after bone marrow transplantation in man. Transplantation. 1987; 43:677–679.

27 27. Jabs DA, Wingard J, Green WR, et al. The eye in bone marrow transplantation. III. Conjunctival graft‐vs‐host disease. Arch Ophthalmol. 1989; 107:1343–1348.

28 28. Tichelli A, Duell T, Weiss M, et al. Late‐onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects. Bone Marrow Transplant. 1996; 17:1105–1111.

29 29. Bacigalupo A, Chien J, Barisione G, Pavletic S. Late pulmonary complications after allogeneic hematopoietic stem cell transplantation: diagnosis, monitoring, prevention, and treatment. Semin Hematol. 2012; 49:15–24.

30 30. Bondeelle L, Bergeron A. Managing pulmonary complications in allogeneic hematopoietic stem cell transplantation. Expert Rev Respir Med. 2019; 13:105–119.

31 31. Crawford SW, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest. 1992; 101:1257–1264.

32 32. Soubani AO, Miller KB, Hassoun PM. Pulmonary complications of bone marrow transplantation. Chest. 1996; 109:1066–1077.

33 33. Cerveri I, Fulgoni P, Giorgiani G, et al. Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed? Chest, 120, 1900–1906.

34 34. Crawford SW, Pepe M, Lin D, et al. Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality. Am J Respir Crit Care Med. 1995; 152:690–695.

35 35. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. New Engl J Med. 2014; 370:1820–1828.

36 36. McClune B, Majhail NS, Flowers MED. Bone loss and avascular necrosis of bone after hematopoietic cell transplantation. Semin Hematol. 2012; 49:59–65.

37 37. Enright H, Haake R, Weisdorf D. Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation. Am J Med. 1990; 89:733–738.

38 38. Socié G, Sélimi F, Sedel L, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. Br J Haematol 1994; 86:624–628.

39 39. Socié G, Cahn JY, Carmelo J, et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Société Française de Greffe de Moëlle (SFGM). Br J Haematol. 1997; 97:865–870.

40 40. Fink JC, Leisenring WM, Sullivan KM, et al. Avascular necrosis following bone marrow transplantation: a case‐control study. Bone. 1998; 22:67–71.

41 41. Bizot P, Nizard R, Socié G, et al. Femoral head osteonecrosis after bone marrow transplantation. Clin Orthop Relat Res. 1998;( 357):127–134.

42 42. Campbell S, Sun C‐L, Kurian S, et al. Predictors of avascular necrosis of bone in long‐term survivors of hematopoietic cell transplantation. Cancer. 2009; 115:4127–4135.

43 43. Weilbaecher KN. Mechanisms of osteoporosis after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2000; 6:165–174.

44 44. Schimmer AD, Minden MD, Keating A. Osteoporosis after blood and marrow transplantation: clinical aspects. Biol Blood Marrow Transplant. 2000; 6:175–181.

45 45. Carpenter PA, Hoffmeister P, Chesnut CH, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2007; 13:683–690.

46 46. Couriel D, Carpenter PA, Cutler C, et al. Ancillary therapy and supportive care of chronic graft‐versus‐host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft‐versus‐host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2006; 12:375–396.

47 47. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002; 288:321–333.

48 48. Rovó A, Tichelli A, Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Cardiovascular complications in long‐term survivors after allogeneic hematopoietic stem cell transplantation. Semin Hematol. 2012; 49:25–34.

49 49. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. New Engl J Med. 1989; 321:784–789.

50 50. Witherspoon RP, Deeg HJ, Storb R. Secondary malignancies after marrow transplantation for leukemia or aplastic anemia. Transplantation. 1994; 57:1413–1418.

51 51. Deeg HJ, Witherspoon RP. Risk factors for the development of secondary malignancies after marrow transplantation. Hematol OncolClin North Am. 1993; 7:417–429.

52 52. Socié G. Secondary malignancies. Curr Opin Hematol. 1996; 3:466–470.

53 53. Socié G, Rizzo JD. Second solid tumors: screening and management guidelines in long‐term survivors after allogeneic stem cell transplantation. Semin Hematol. 2012; 49:4–9.

54 54. Cohen JI. Epstein‐Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore). 1991; 70: 137–60.

55 55. Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi‐institutional study. Blood. 1999; 94:2208–2216.

56 56. Zutter MM, Durnam DM, Hackman RC, et al. Secondary T‐cell lymphoproliferation after marrow transplantation. Am J Clin Pathol. 1990; 94:714–721.

57 57. Schouten HC, Hopman AH, Haesevoets AM, Arends JW. Large‐cell anaplastic non‐Hodgkin’s lymphoma originating in donor cells after allogenic bone marrow transplantation. Br J Haematol. 1995; 91:162–166.

58 58. Meignin V, Devergie A, Brice P, et al. Hodgkin’s disease of donor origin after allogeneic bone marrow transplantation for myelogeneous chronic leukemia. Transplantation. 1998; 65:595–597.

59 59. Rivet J, Moreau D, Daneshpouy M, et al. T‐cell lymphoma with eosinophilia of donor origin occurring 12 years after allogeneic bone marrow transplantation for myeloma. Transplantation. 2001; 72:965.

60 60. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin’s disease after allogeneic bone marrow transplantation. J Clin Oncol. 1999; 17:3122–3127.

61 61. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. New Engl J Med. 1997; 336:897–904.

62 62. Bhatia S, Louie AD, Bhatia R, et al. Solid cancers after bone marrow transplantation. J Clin Oncol. 2001; 19:464–471.

63 63. Socié G, Scieux C, Gluckman E, et al. Squamous cell carcinomas after allogeneic bone marrow transplantation for aplastic anemia: further evidence of a multistep process. Transplantation. 1998; 66:667–670.

64 64. Daneshpouy M, Socie G, Clavel C, et al. Human papillomavirus infection and anogenital condyloma in bone marrow transplant recipients. Transplantation. 2001; 71:167–169.

65 65. Curtis RE, Metayer C, Rizzo JD, et al. Impact of chronic GVHD therapy on the development of squamous‐cell cancers after hematopoietic stem‐cell transplantation: an international case‐control study. Blood. 2005; 105:3802–3811.

66 66. Leisenring W, Friedman DL, Flowers MED, et al. Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. J Clin Oncol. 2006; 24:1119–1126.

67 67. Cohen A, Rovelli A, Merlo DF, et al. Risk for secondary thyroid carcinoma after hematopoietic stem‐cell transplantation: an EBMT Late Effects Working Party Study. J Clin Oncol. 2007; 25:2449–2454.